Alzheimer's Drug Shows Promise in Early Results of Study

Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study

soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease’s progress in a late-stage study.

The drugmaker said early results showed that its treatment, lecanemab, reduced patient clinical decline by 27% when compared to a placebo or fake drug after 18 months of the infused treatment. Patients were monitored using a scale that measures how they do in areas like memory, judgement, problem solving and personal care.

The company is already seeking an accelerated approval from the U.S. Food and Drug Administration, and the agency is expected to decide by early next year. Eisai and Biogen will co-promote the drug.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

TIME /  🏆 93. in UK

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Experts encouraged by Alzheimer drug preliminary dataExperts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.
Read more »

Observing SARS-CoV-2 Omicron reinfections with different sub-variantsObserving SARS-CoV-2 Omicron reinfections with different sub-variants SARSCoV2 COVID19 Omicron Reinfection CDCgov
Read more »

Alzheimer's-slowing drug labelled historicTrial results of a drug appearing to slow Alzheimer's disease represent a 'historic moment', experts say.
Read more »